PXS-6302

PXS-6302 is a topically administered, irreversible small molecule inhibitor of the lysyl oxidase (LOX) family of enzymes, developed for the treatment of skin scarring and potentially other fibrotic conditions. LOX enzymes catalyze collagen crosslinking, which is central to scar formation and tissue stiffness. By inhibiting these enzymes, PXS-6302 reduces collagen deposition and cross-linking in scar tissue, leading to improved extracellular matrix composition that more closely resembles normal skin. In preclinical models (murine and porcine), topical application reduced scar formation without compromising tissue strength. Clinical studies have shown significant inhibition of LOX activity (~66%), reduction in hydroxyproline (a marker for collagen), and favorable safety/tolerability with only localized skin reactions reported. The drug was originally discovered by Pharmaxis and is now being developed by Syntara Limited[1][2][3][4][5][6].